# A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

> **NCT06498518** · PHASE2 · WITHDRAWN · sponsor: **Karen Carty**

## Conditions studied

- Neoplasms Pancreatic

## Interventions

- **DRUG:** IMM-101, Pembrolizumab, Gemcitabine

## Key facts

- **NCT ID:** NCT06498518
- **Lead sponsor:** Karen Carty
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-17
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-05-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** One of the pharmaceutical partners (Immodulon) went into administration, the company which bought the assets confirmed to the study team on 23rd May 2025 they were not in position to support the study. Study terminated early
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498518, "A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06498518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*